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50 Years After Nifurtimox: Current and Future 
Chemotherapy For Chagas Disease 
 
ABSTRACT 
 
 American trypanosomiasis, commonly called Chagas disease, is one of the most neglected 
illnesses in the world and remains one of the most prevalent chronic infectious diseases of Latin 
America with thousands of new cases every year. The only treatments available have been introduced 
five decades ago. They have serious, undesirable side effects and disputed benefits in the chronic stage 
of the disease – a characteristic and debilitating cardiomyopathy and/or megavisceras. Several 
laboratories have therefore focused their efforts in finding better drugs. Although recent years have 
brought new clinical trials, these are few and lack diversity in terms of drug mechanism of action, thus 
resulting in a weak drug discovery pipeline. This fragility has been recently exposed by the failure of 
two candidates; posaconazole and E1224, to sterilely cure patients in phase 2 clinical trials. Such 
setbacks highlight the need for continuous, novel and high quality drug discovery and development 
efforts to discover better and safer treatments. 
 In this article we will review past and current findings on drug discovery for Trypanosoma cruzi 
made by academic research groups, industry and other research organizations over the last half century. 
We will also analyze the current research landscape that is now better placed than ever to deliver 
alternative treatments for Chagas disease in the near future. 
 
 
KEYWORDS 
Trypanosoma cruzi, Chagas disease, benznidazole, nifurtimox, drug discovery, chemotherapy. 
 
1. INTRODUCTION 
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 Chagas disease is named after the Brazilian physician Carlos Chagas who first described the 
disease in 1909 [1]. Chagas disease is caused by the parasite Trypanosoma cruzi and is considered to 
be the parasitic infirmity with the biggest social and economic burden in Latin America [2, 3]. There is 
an estimate of 7-8 million people currently infected with T. cruzi, while there are approximately 25 
million people at risk of acquiring the disease [4]. Every year, Chagas disease claims 10,000 deaths in 
endemic countries [5]. The parasite has a complex life cycle, alternating between the mammalian host 
and the hematophagous triatomine insect vector. The infection begins when the infected bug feeds on 
the host, which can be a wild or domestic mammal or a human. Infective metacyclic trypomastigote 
forms of T. cruzi are found in the feces of the bug which are released during the blood meal, and gain 
access through the lesion to infect dendritic cells [6]. Once inside a cell, the parasite breaks free of its 
entering organelle, the endosome/lysosome, and differentiates into a replicative amastigote form. The 
amastigote divides several times and maturates into bloodstream trypomastigotes that rupture the host 
cell and are released into the bloodstream or lymph, free to infect a wide range of cells or be ingested 
by the transmitting vector, thus closing the cycle. In the triatomine gut, the parasite transforms once 
again into a replicative stage called the epimastigote and after clonal divisions it migrates to the final 
portion of the intestine and differentiates again into infectious metacyclic trypomastigote. 
 Although vectorial transmission has been greatly reduced due to vector control campaigns carried 
out by the World Health Organization (WHO), the Pan-American Health Organization (PAHO) and 
national health ministries of participating countries, there are still about 41,000 [5] new cases each year 
due to vectorial transmission. Many thousands of cases can be also attributed to secondary infection 
routes like transfusion of contaminated whole blood and derivate products, transplant of organs from 
chronically infected patients, congenital and oral transmissions. Oral transmission is a growing 
concern, with 138 outbreaks responsible for the appearance of 776 new cases in the period of 2000 – 
2010. Oral infection is usually acquired through ingestion of food, sugar cane and other juices, water or 
soup contaminated with infected triatomines or their feces [7]. Human migration in recent years have 
increased the incidence of new cases in non-endemic countries, making Chagas a health and medical 
problem in North America, Europe, Japan and Australia, requiring governments to implement 
screenings for blood and organs donations, as well as implement infrastructures to treat infected 
patients [8]. 
Due to the huge vertebrate reservoir and the variety of triatomine insects, the eradication of this 
zoonotic parasite is practically impossible [9]. 
 The symptomatology of Chagas disease may vary according to the route of infection: while 
vectorial transmission is usually asymptomatic or presents nonspecific symptoms, oral infection may 
increase the chance of acute cardiomyopathy because of the higher parasite loads associated.   About 
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20 to 30% of acute cases develop serious chagasic cardiomyopathy with evolving symptoms and the 
risk of sudden death [10]. Fifteen to 20% develop digestive tract manifestations. The remaining 
infected individuals are considered to have the indeterminate form of the disease and the majority may 
not have symptoms or signs of the disease for all their life [10]. 
 To treat new acute cases, intermediate phase patients or reactivations from chronic patients, the 
only drugs available were introduced more than four decades ago, with no alternatives. Benznidazole 
and nifurtimox (Figure 1A & B) are effective in treating acute infections, but efficacy is thought to 
decrease with the disease progression, with little to no effect in the chronic phase. Additionally, they 
must be administrated for long periods of time and display numerous side effects. Some of the most 
serious side effects require monitoring and ultimately, treatment interruption.  
 For the above reasons, new drugs to fight this disease are a dire need. New formulations of old 
drugs, old drugs with new applications as well as innovative drugs are feeding the pipeline for the 
treatment of Chagas disease [11]. 
In the following sections we will discuss the therapies available today and their limitations 
followed by the advances in the drug discovery and the candidates currently in preclinical and clinical 
studies to treat Chagas disease. 
 
2. CURRENT THERAPIES 
 
2.1BENZNIDAZOLE 
 Benznidazole (figure 1A) is a nitroimidazole (N-benzyl-2-(2-nitro-1H-imidazol-1-yl)acetamide) 
discovered in 1972 at Roche Laboratories, was and originally marketed as Rochagan
TM
 or Rodanil
TM
. 
Despite its age, it is still the front-line treatment for the disease, although it is not approved by FDA 
[12]. Benznidazole is considered to be effective in reducing symptom severity and to shorten the 
clinical course and the duration of detectable parasitemia. Clinical cures are thought to be achieved in 
60 to 85% of the acute cases and in more than 90% of congenitally infected infants, if treated in their 
first year of life [13]. Efficacy of benznidazole in chronic Chagas disease is still debatable, with reports 
varying from 15 - 35% of cure rates [14, 15]. The benefits of the drug in preventing cardiac and/or 
megacolon and megaesophagus manifestations are not yet clear [16]. To address this uncertainty, a 
large, multicenter, double-blind, randomized, placebo-controlled clinical trial called BENEFIT (The 
Benznidazole Evaluation For Interrupting Trypanosomiasis, ClinicalTrials.gov, ID: NCT00123916) 
with 3,000 patients in several endemic countries is underway and will evaluate the efficacy of a daily 
dose during 40 to 80 days of treatment in reducing mortality and morbidity in patients with chronic 
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Chagas cardiomyopathy [17]. Problems with precise dosing in young children and the adverse effects 
observed has led to the development of a new pediatric formulation of benznidazole. This lower dose, 
easily dispersible tablet that should improve dosing accuracy, safety, and adherence to treatment is 
currently in clinical trials (Population Pharmacokinetics Study of Benznidazole in Children With 
Chagas'Disease - Pop PK Chagas, ClinicalTrials.gov, ID: NCT01549236) [18]. 
 The mechanism of action of benznidazole is thought to require the reduction of its nitro group by 
parasite nitroreductases, and in the process originate free radical intermediates and electrophilic 
metabolites that react with proteins, lipids and DNA that disrupt normal cell function and metabolism. 
It is also thought that T. cruzi NADH-fumarate reductase inhibition, phagocytosis improvement and 
death by INF-γ are additional mechanisms involved in parasite killing by benznidazole [19]. On the 
other hand, reduction by human liver NADPH, cytochrome P-450 reductase, P450, xanthine oxidase 
and aldehyde oxidase are thought to be responsible by the adverse side effects in patients [20].  
 Benznidazole is very toxic, but remains one of the few drugs with nitroaromatic groups still in 
use today [21] from where it derives its major toxicity. This toxicity is the main reason why 
benznidazole is far from an optimal drug and why new drugs are urgently needed.  The most common 
side effect is dermatitis from hypersensitivity to the drug, the later appearing in 20 to 25% of the 
patients, usually after 10 days on the treatment, and for this reason, onwards weekly monitoring is 
recommended [22]. Digestive intolerance, peripheral neuropathy, depression of bone marrow, toxic 
hepatitis and lymphomas are other occurring side effects. Treatment interruption is most frequently due 
to dermatitis and digestive intolerance, although studies reveal that low-fat and hypoallergenic diet and 
daily dose administrations can reduce their incidence [22]. In addition, benznidazole should not be 
administered to pregnant women nor patients with severe renal or hepatic dysfunction, because of drug 
metabolization by these organs [23]. 
 Strains resistant to benznidazole have been reported and are a major and increasing concern. An 
example is the Colombian strain, with benznidazole only being able to cure up to 16% of the mice 
infected with different clones [24]. In vitro results using real-time PCR suggest nitroreductases (NTRs) 
as the main mechanism of resistance in vitro, probably due to loss of a NTR gene copy [25]. A recent 
study warns of the relative ease in which benznidazole can develop resistance in vitro by a couple of 
different mechanisms such as chromosome loss and different point mutations in the NTR gene, all 
arising from a single population [26]. 
 
2.2 NIFURTIMOX 
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 Nifurtimox (N-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitrofuran-2-yl)methanimine) a 5-
nitrofuran derivative (figure 1B), constitutes the second and only alternative to benznidazole for the 
treatment of Chagas disease. Its use is also not approved by the FDA either. Also known as Bayer 
2502, the drug, marketed as Lampit
TM
, was originally discovered in that pharmaceutical company in 
1965, exactly 50 years ago and provided, for the first time, a treatment for chagasic patients. It is also 
used in combination therapy with eflornithine to treat second stage African trypanosomiasis caused by 
the parasite strain Trypanosoma brucei gambiense [27, 28]. 
 Nifurtimox efficacy is similar to benznidazole, but it has a much higher frequency of adverse 
effects. There is a frequency of adverse effects in 98% of patients, with only 56% of them completing 
the 60-day course treatment and 29% not tolerating it for more than 30 days. Digestive symptoms are 
predominant and neurological alterations the most persistent. An estimated 7% of patients had severe 
adverse effects like angioedema, myocarditis and grade-3 anaphylactic reactions [29]. 
Recently, a study highlighted the possible biochemical mechanisms that may be associated with 
some of nifurtimox adverse side effects and as well as from other nitro-aromatic derived drugs [30]. 
 Similar to benznidazole, nifurtimox also acts through a mechanism of intracellular nitro reduction 
with the generation of the nitro radical, followed by redox cycling. In contrast, there is a greater role 
for oxygen reactive species, like superoxide ion and hydrogen peroxide which are toxic to T. cruzi. 
This parasite is sensitive to oxidative stress due to weak detoxification mechanisms due to the absence 
of catalase or peroxidase activity and reduced superoxide dismutase activity [19, 31]. RNA 
interference studies on Trypanosoma brucei, responsible for Human African Trypanosomiasis, show 
that besides NTR, other proteins linked to ubiquinone synthesis are also involved in nifurtimox 
mechanism of action in that species, and it is likely that the same mechanism is also present in T. cruzi 
[32]. 
 Resistance to nifurtimox is readily obtainable in vitro and it seems parasite nitroreductases play a 
major role in its resistance, mounting up evidence that cross-resistance with benznidazole can occur as 
has been reported [33, 34], increasing the pressure to find alternative drugs to treat patients refractive 
to the only available therapies. 
 The renewed interest in nitro-heterocycles has spurred research into finding alternative nitro-
heterocycles, these include heteroallyl-containing 5-nitrofuranes, 5-nitrofuryl containing 
thiosemicarbazones and 2- or 3-nitro-1H-imidazole-based amides and sulfonamides. Despite some of 
these compounds being 10-50 times more potent than nifurtimox, they too seem to have the same 
issues of cross-resistance [35-37]. However, some recently synthesized novel nitrofuran amides, which 
are up to a 1000-fold more potent than nifurtimox, with excellent selectivity, have a trypanocidal 
activity that seems to be independent of nitroreductase activity [38]. 
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3. DRUG DISCOVERY AND DEVELOPMENT FOR CHAGAS 
DISEASE 
 
3.1 DRUG DISCOVERY STRATEGIES 
  
 Various approaches can be adopted when considering developing drugs for neglected diseases 
Nwaka and Hudson 
39
: (i) “De novo synthesis” is the classical way that focuses on the identification of 
new chemical entities through target discovery and compound screening. Although this is a very 
important strategy in the discovery of novel drugs for neglected diseases, it is a long-term approach 
and usually has constrains like high risk, high attrition rate of candidate compounds and needs high 
human and financial resources. Because of that and the perspectives of low market return and profits, 
the majority of companies do not make neglected tropical diseases a priority [40]. Populations affected 
by neglected diseases, and Chagas disease in particularly, are very poor and don’t have the means to 
pay for expensive medication [41]. (ii) “Piggy-back” discovery is the process that takes advantage of 
the development of drugs for other diseases that may share some mechanistic identity in terms of 
molecular target, providing strong chemical start points to be followed and developed in the next 
phases. An example is the use of kinase inhibitors research data from cancer treatment to provide 
shortcuts for the development of a kinase inhibitor versus a parasitic target (iii). Label extension or 
drug repurposing is the approach that has some of the most immediate results, in that it uses already 
approved drugs for some pathologies, and repurposes them to be used in neglected diseases, saving 
considerable time and costs for approval processes after efficacy confirmation. Most of the 
toxicological data and sometimes, clinical tests are already available. An example of successful 
application of this strategy is the case of praziquantel for schistosomiasis and ivermectin for 
filariasis/onchcocersiasis [39, 42]. More recently, Auranofin, an approved drug for rheumatoid 
arthritis, has been identified as an amebacide [43] and a clinical trial is being launched in Bangladesh. 
 Independently of the strategy used, an essential feature of the drug discovery process that plays a 
guiding role is the target product profile (TPP). TPPs are a set of criteria to be followed through the 
development process and describe the needs and characteristic that the new candidate has to meet in 
order to constitute an improvement over the current available therapies. Drugs for Neglected Diseases 
initiative (DNDi), a non-profiting drug research and development organization founded with the 
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objective to develop therapies for neglected diseases, has recently updated a TPP for Chagas disease 
[44]. 
 
3.2 STARTING POINTS: SCREENING FOR HITS 
 
 Hits is the name given to the compounds that are first identified in a screening as interesting 
molecules able to yield a positive read or specific phenotype, usually in a similar way to a positive 
control or reference drug. Two different approaches can be taken to identify these starting points for 
drug discovery: a molecular target or target-based approach, and a phenotypic approach, also known as 
untargeted drug discovery. Target-based drug discovery relies on the previous discovery and 
characterization of a given molecular target and subsequent target validation by chemical or genetic 
means. Each has advantages and disadvantages [45]. Ideally, a target should be validated by more than 
one method. Chemical and biochemical validation is the proof that a molecular target, usually a 
protein, is able to be inhibited by a small molecule and that the use of such molecule in the parasite 
and/or in vitro and in vivo models of the disease leads to deficient parasite grow or ability to establish a 
normal infection. Genetic validation implies the reduction or elimination of the molecular target at the 
cellular level and the consequent observation of the interference in the parasite fitness/survival. The 
only reliable way to genetically validate a protein target in T. cruzi is by gene-knockout. A selection 
marker - a coding sequence of a gene that confers resistance to a given antibiotic used to select 
parasites - is cloned between two homologous regions of the locus to eliminate, in a way that when the 
DNA is electroporated into the parasite, homologous recombination occurs with the substitution of the 
endogenous gene by the exogenous selection marker. Because of the low recombinogenic potential of a 
parasite and slow growth kinetics, these transgenic techniques are extremely hard and time consuming 
to perform, with high failure rates and many weeks just to select stable transfected cells [46]. There are 
only two genes, which code to oligopetidase B and N-myristoyltransferase that have been properly 
genetically validated and only the later seems to be interesting to explore as a drug target [47, 48]. 
Unfortunately and unlike the related species Trypanosoma brucei, T. cruzi does not have functional 
RNAi machinery. Apparently some of its components have been lost or mutated during evolution [49, 
50]. Most recently, and in the wake of a revolution in genome editing technology, CRISPR-Cas9 
technology has been successfully applied to T. cruzi with major breakthroughs like expression 
knocking down of an enzyme gene family consisting of 65 members [51]. 
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After proper drug target validation, biochemical assays can be set up to screen for inhibitors. 
These assays usually make use of proteins, frequently of recombinant origin. In the past, many of the 
labs working with T. cruzi have screened only a small quantity of compounds, from either synthetic or 
natural origin, because of the limited access to large compound collections. As a consequence, the 
small, scattered and independent scale of the efforts greatly reduces the chances of discovering 
interesting compounds.  
The scenario changed dramatically with the development of high throughput technology based on 
assay miniaturization and automation of protocols, from procedure to analysis, thus opening the door 
to large scale screening campaigns for this parasite. Among the improvements are time saving, since 
many compounds are tested in simultaneous, assay cost reduction, and data reproducibility. As an 
example, one high-throughput screen of 200 000 compounds against cruzipain, yielded 921 hit 
compounds that were subsequently screened by computational docking analysis and revealed 5 
chemical scaffolds of common hits. These scaffolds are good starting points for further optimization 
and evidentiate the advantages of combining biological and bioinformatics analysis for priorization of 
molecules after an high-throughput screening campaign has been performed [52]. In another example 
of target-based drug discovery, CYP51 from Mycobacterium tuberculosis was screened against a 
library of 20 000 organic compounds and resulted in two very active compounds [53], of which one 
(ChemDiv C155-0123) later showed selective inhibitory activity against the T. cruzi orthologous 
enzyme [54]. 
The big limitations of molecular target approaches are the possibility of poor disease linkage, low 
or impossible druggability of the target, risk of off-target effects that may translate into significant 
toxicity and the chance of overlapping research by differe t groups since there are so few targets 
characterized [55]. 
To circumvent such limitations, phenotypic base approaches have been developed. Instead of a 
single molecular target, whole cells are tested directly with the compounds and selection is made based 
on the observance of the required phenotype. This allows the selection of only those compounds that 
are active against the parasite, despite their mechanism of action. Also, it readily selects those 
compounds with the minimal pharmacodynamic and pharmacokinetic properties needed: proper 
intracellular distribution and accumulation, physiological binding and inhibition to target, etc., that are 
very difficult to predict with target-based strategies. However, this method requires that the target must 
be elucidated in the discovery process, a task not always easy but achievable [56]. The most recent 
trend in whole-cell assays has employed the use of high-content screening analyzers – automated 
microscopes that can image many conditions (compounds) in clear bottom culture microplates. When 
the technology appeared one assay was developed that made use of mammalian cells expressing GFP 
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and parasites stained with DAPI, and both manual and automated data analysis was performed [57]. 
With critics of genetically modified parasites/host cells and the further development of technology an 
improved assay was developed that used whole unmodified cells and parasites. This assay was 
validated with a small library of FDA-approved drugs [58]. The development of analysis software 
further automates the campaigns and allows the additional mining of important data, for example, the 
toxicity for host cells [59]. The first multi-thousand screening campaign described in the literature has 
been recently published [60].  
Balancing the benefits and disadvantages of both strategies in hit identification for parasitic 
diseases such as Chagas, experts lean towards phenotypic approaches as the most promising 
methodologies [39] in which hits are selected for their ability to kill or not the parasite, coupled with 
cytotoxicity evaluation. In fact, when we take a look at the recent first-in-class new drugs with 
innovative molecular mechanism of action, we see that many of these drugs were discovered by 
phenotypic screening (28 vs. 17) [61]. The development of such high-throughput, high-quality, cheap 
and reliable assays like the described above is considered one of the biggest contributions to the 
advance of the Chagas disease drug discovery effort. 
 
3.3 FROM HIT TO LEAD AND BEYOND 
  
 Once hits have been obtained, the most promising are further confirmed with the same assay in a 
dose response-curve to confirm activity and interpolate the EC50 value, a measure of the potency of the 
compound that is the concentration of a compound where 50% of its maximal effect is observed. Most 
guidelines indicate an EC50 lower than 10 µM as a good starting value, although recommendations can 
vary if other criteria are met, like a high selectivity index, for instance. The confirmed hits can also be 
subject to complementary activity assays. These can be of a different configuration, employ a different 
readout, or even access activity against other strains. A recent paper shows that a set of compounds in 
clinical trials have significantly different activity profiles depending on the strain they are tested on 
[62]. As has been discussed above, it is a requisite of the TPP for Chagas disease that a future drug is 
active against a large set of different DTUs. Another key unanswered question is whether a compound 
must clear the infection totally, as the reference compound, benznidazole, does. Does total clearance of 
infected cells, or parasites in animals or humans correlate with multistrain activity or, more 
importantly, with the clinical course of disease in the subsequent 20 years? Compounds that still meet 
an agreed upon pharmacological and biological properties are called lead compounds. Leads are at the 
end of the screening campaign, but are the starting points of yet another phase in the drug discovery 
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and development called lead optimization. In this phase, compounds enter a cycle of further testing, 
commonly with in vivo testing of activity and toxicity, and are in parallel modified and optimized with 
medicinal chemistry to try to improve potency, selectivity, reduce toxicity and enhance 
pharmacokinetic parameters [40]. The medicinal chemistry necessary for lead optimization is very 
costly and constitutes a bottleneck for many drug discovery efforts. Few in academia have the 
resources or access to the synthetic chemistry capacity necessary to produce the tens to hundreds of 
compounds usually required for lead optimization. Organizations such as DNDi and recently launched 
consortia-based projects like the FP7 (Seventh Framework Program supported by the European 
Commission) KINDReD (Kinetoplastid Drug Development), NMTrypI (New Medicines for 
Trypanosomatidic Infections), PDE4NPD (Phosphodiesterase Inhibitors for Neglected Parasitic 
Disease) and A-PARADISE (Anti-Parasitic Drug Discovery in Epigenetics) have attempted to address 
this issue by coordination or outsourcing. 
 The optimized lead compound is one which can be called a pre-clinical candidate and enter the 
pre-clinical phase. 
 
 
3.4 ANIMAL MODELS 
 
Animal models are used to extract the maximum possible information on drug efficacy and 
toxicity before testing the drug candidates in humans. Since the translation of data is of the utmost 
importance, several animal models have been studied to reproduce the physiopathology of Chagas 
disease. Models like mouse, rat, rabbit, dogs and non-human primates have been tried, but none of 
them completely mimics what happens in the human host [63]. The rat has been used in the past, but 
early observations concluded that it is somewhat resistant to T. cruzi infection, developing a mild and 
slow pathology [64]. Rabbits proved to be capable of developing some of the chronic alterations such 
as focal myocarditis with a fibrous nature, but did not show more severe forms of chronic myocarditis 
or severe histological lesions in digestive track and skeletal muscles found in typical infections [65]. 
The Syrian hamster has also been proposed as an animal model for chronic Chagas cardiomyopathy. It 
was not able to display all the characteristics findings of human cases [66]. Dogs, on the other hand, 
develop most of the clinical aspects of the disease found in humans, in particular the indeterminate 
form characterized by a latent infection, without disease symptoms and with normal 
electrocardiograms; just a fraction of the animals develop chronic phase symptoms [67, 68]. However, 
this is a disadvantageous characteristic of the dog model when the larger amount of time and number 
of animals needed to obtain enough chronically infected dogs is considered in terms of the discovery 
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process. Monkeys are phylogenetically the closest related species to be used to study Chagas disease. 
Similarly to other pathologies like Leishmaniasis and HIV, Chagas disease findings in these animals 
are easily extrapolated to the humans [68, 69]. 
 For the above reasons, the mouse has remained the preferred animal model. Mice are easy to 
handle, house and are cheaper. Additionally, mouse models resemble many immunological, 
pathological and physiological aspects of human Chagas disease. One of the commonly used strains in 
chemotherapy is Swiss mice, an outbred strain very sensitive to diverse T. cruzi genotypes [70]. 
Regarding inbreed strains, Balb/C has also been extensively used and is considered one of the most 
susceptible to parasite infection in general [71]. C3H are a mildly resistant mouse strain commonly 
used to obtain chronic-like infection in these animals [72]. C57BL/6 are considered to be among the 
most resistant strains, although susceptibility can vary widely depending on the strain of trypanosome 
used [73]. This genetic background is frequently used to obtain chronically infected mice in attempts to 
reproduce the pathophysiology of the human disease. 
 The obtention of a valid model for chronic Chagas disease remains one of the biggest challenges 
in research. Current chronically infected mouse models develop an anti-inflammatory infiltrate and 
fibrosis in the heart, hallmarks of the disease in humans, but development of a model closely 
resembling human chronic Chagas cardiomyopathy with extensive fibrosis, segmental myocardial 
abnormalities and macroscopic ventricle dilatation after a period of absence of signs is still to report 
[66]. According to current protocols, four strategies have been employed to try to mimic chronic 
Chagas disease in mice: (a) a combination of susceptible mice strain, pathogenic T. cruzi DTU, age of 
animals and inoculation route that guarantees the survival of the animals to the acute phase; (b) 
infection of mice with a lethal dose of T. cruzi followed by the treatment with a reference drug that 
assures animal survival, but not parasite clearance; (c) infection of resistant strains of mice with sub 
lethal inoculum of low pathogenic DTU; (d) infection of animals immunized by attenuated strains with 
a pathogenic DTU [74]. 
 There are also dozens of different T. cruzi strains that have been used in animal models of the 
disease. Each research group works with a limited set of biological specimens that may reflect the 
history of the lab. An illustrative example of this variability is the case of A/J and C3H/HePAS mice 
infected with the same clone of Sylvio X10/4. Distinct histopathological findings are reported, 
suggesting a host genetic role in the manifestations and progress of the disease [75]. This variability 
hinders the extrapolation of results to other animal models and ultimately, to humans. 
 Recent guidelines for in vivo testing of compounds in Chagas disease drug discovery have been 
elaborated. One protocol suggests three independent and consecutive in vivo evaluations of drug 
candidates: (1) testing for the effect of the compound on parasitemia reduction using Swiss female 
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mice infected with Y strain, three doses of compound with the highest one set at the maximum 
tolerated dose, orally or intraperitonially, and after five days of infection for a duration of five 
consecutive days; (2) analysis of parasitological cure during the acute phase using Swiss female mice 
infected with Y strain, with the dose established in the previous stage; (3) cure the acute phase of 
parasitemia caused by Colombian strain, which is benznidazole resistant [76]. Parasitemia is analyzed 
at 5, 8 and 10 days post infection (dpi) for (1) and (2) and at 20, 25 and 30 dpi for (3). Mortality is 
evaluated for all the three phases at 30 days and PCR, after immunosuppression with 
cyclophosmamide, to detect “latent” parasites. This technique was employed because it was proved to 
be more sensitive and time-efficient than haemoculture. All the tests are done against a positive control 
of 100 mg benznidazole per kilogram of weight per day [76]. 
 The effectiveness in the chronic and indeterminate stage comes further on the development 
process, and the lack of it does not invalidate the drug since, if the TPP is followed, it should be 
already an advance over existing therapies. 
 
3.5 BIOMARKERS 
 
Another obstacle in the drug discovery for Chagas has been the lack of reliable biomarkers of 
cure. Traditionally, the definitive test of cure relies on conventional serology methods that have the 
limitation that it can take many years for the seroconversion to take place. Also, the majority of 
currently used methods employ crude antigen preparations from parasite life-cycle stages not present in 
the mammalian host. Polymerase chain reaction is the standard method of cure in the current clinical 
trials and although useful, there is no proof of efficacy and it is only an indication of sterile cure for a 
given therapy [77]. Newer tests using recombinant proteins or peptides may be an improvement, but 
results are often inconsistent [78]. A recent a promising discovery in the field has been the 
identification of unusual fragments of human apolipoprotein A1 (APOA1) that are specifically present 
in chagasic patients and seem to disappear after treatment with nifurtimox [79, 80]. In mouse models, 
different methodologies to access parasitological cures were used after treatment with benznidazole 
and found out that even mice considered cured by hematological criteria still showed positive PCR 
tissues, either indicating a residual infection or residential parasite nucleic acid [81].  
 
4. TARGET CANDIDATES IN THE PIPELINE 
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4.1.ERGOSTEROL BIOSYNTHESIS INHIBITORS 
 Inhibitors of sterol 14 α-demethylase (CYP51) constitute a major fraction of all the drugs in the 
Chagas disease pipeline [11]. This enzyme is involved in the de novo synthesis of sterols in T. cruzi. 
Sterols are membrane lipids present in eukaryotes and have essential functions such as control of 
membrane fluidity and permeability, signal transduction and modulation of membrane-bound enzyme 
activity [82]. While in mammals the major sterol is cholesterol, in plants, fungi and protozoa the major 
sterol present is ergosterol. The difference consists of a second double bond at the B ring and a fully 
saturated side chain with a methyl group at C24 in cholesterol [83]. CYP51 catalyzes a critical step of 
this biosynthetic pathway, removing the C14 methyl group from the sterol intermediate eburicol and 
originating 14α-demethyl-14dihydroeburicol [84]. 
 Ergosterol biosynthesis inhibitors are among the most common drugs used to treat fungal 
infections, and after the validation of this pathway in T. cruzi, compounds that were originally 
developed as antifungals were tested against the parasite. While some of the early generations 
imidazoles (e.g. miconazole, ketoconazole) and triazole (e.g. itraconazole, fluconazole) sterol 
biosynthesis inhibitors have some attenuating effect on the infection, they failed in achieving 
parasitological cures [85].  However, as newer azoles to treat fungi infections are still an ongoing 
interest for pharmaceutical companies, latest generations drugs have also been tested for anti-T. cruzi 
activity. 
 One of the most promising molecules of the past decade was posaconazole (figure 2A). This 
triazole originally marketed as Noxafil by Schering-Plough pharmaceutical and active against Candida 
spp. and Aspergilus spp. is one example of the previously described drug repurposing strategy. Early 
assays demonstrated its potent and specific in vitro activity against T. cruzi, especially against the 
amastigote stage. Moreover, the effect on murine acute and chronic models was curative, rather than 
suppressive, as some earlier tested antifungal compounds demonstrated [86]. Later, posaconazole also 
proved to be an efficient trypanocidal against benznidazole and nifurtimox resistant strains, even in 
immunosuppressed mouse models, where the parasite would have a favorable environment to multiply 
[87]. A comparative study between posaconazole and benznidazole in a mouse model of Chagas 
disease showed both drugs led to 100% survival rates, suppression of parasitemia and negative T. cruzi 
antibodies. Only posaconazole-treated mice had completely negative haemocultures 54 dpi, whilst 50% 
of the benznidazole-treated had positive results. Also, plasma enzymatic assessment of cardiac lesion 
was indistinguishable from uninfected control for posaconazole, but significantly higher for 
benznidazole [88]. These promising results led to two clinical trials: one phase 2 trial sponsored by 
Hospital Universitari Vall d'Hebron Research Institute (ClinicalTrials.gov, ID: NCT00349271, 
CHAGASOL) that evaluated posaconazole and benznidazole for the treatment of Chagas disease 
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chronic infection [89] and a phase 2 trial by Schering-Plough (now merged with Merck & Co.) for the 
treatment of asymptomatic Chagas disease, comparing a posaconazole with a placebo regimen and a 
combination of posaconazole with benznidazole (ClinicalTrials.gov, ID: NCT01377480, STOP 
CHAGAS) [90]. When evaluating posaconazole in patients, it is noteworthy that a woman with chronic 
Chagas disease and systemic lupus erythematous requiring immunosuppression, was treated with 
posaconazole eliminating T. cruzi completely, whereas benznidazole treatment failed in this patient 
[91]. 
Unfortunately, the first clinical trial of posaconazole in humans did not replicate the results reported for 
the first patient. The treatment, consisting of two doses delivered orally for 60 days, had initial marked 
antitrypanosomal activity in chronic Chagas disease affected patients, but follow-up at the end of 
treatment suggested reactivation of infection, as documented by PCR. All but one patient treated with 
benznidazole showed negative PCR. The second clinical trial has finished in January 2015 and the 
final results should be published soon thereafter. 
The activity of posaconazole is attributed in part to its pharmacokinetic characteristics, with a 
large volume of distribution and long terminal half-life, coupled with the fact that this lipophilic drug 
accumulates in cell membranes. This is expected to give high local concentrations of the drug to 
interact with the membrane-bound CYP51 target [92]. A drawback is the difficult synthesis of 
posaconazole and the associated costs of about €8,000 per treatment, a value that clearly is 
incompatible with the economical impoverished majority of the population affected [91].  
Another ergosterol biosynthesis inhibitor in the recent pipeline was E1224 (figure 2B) from Eisai 
Co. E1224 is the monolysine salt of ravuconazole, thus a pro-drug of an antifungal with a short half-
life. In this trial, which began in Bolivia in July 2011 as a partnership of DNDi and Eisai, adults with 
chronic “intermediate” Chagas disease were given placebo, E1124 or benznidazole (ClinicalTrials.gov, 
ID: NCT01489228). A series of examinations were then carried out in the following months in order to 
evaluate parasitological cures [93]. According to DNDi, the drug failed to maintain sustained efficacy 
1 year after the end of treatment. The advantage of E1224, was that the structure of this compound was 
simpler and thus synthesis should be less expensive.  
 A third ergosterol biosynthesis inhibitor in clinical trials is Tak187 (figure 2C), a triazole 
synthetized in the 1990’s and the property of Japanese Takeda Chemical Industries. There was 100% 
survival in the acute model of Chagas disease in mice treated with Tak-187 as well as a very high 
parasitological cure (80%). In the chronic model, not all mice survived, but those that did there was 
100% parasitological cures even with benznidazole and nifurtimox resistant T. cruzi strains [94]. 
Subsequent studies confirmed that the drug could produce reductions of parasitemia similar to 
benznidazole, but at 10 times less dosage. Furthermore, it was superior to benznidazole in reducing 
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inflammatory infiltrates and tissue damage in the heart and skeletal muscle of infected mice. The 
superior efficacy was attributable to higher intrinsic activity and long terminal half-life [95]. Tak-187 
has completed phase I trials [11].  
 The fungicide fenarimol, another inhibitor of CYP51, has been found to affect T. cruzi growth. 
After synthesis of analogues, the most promising compounds were tested in vivo in a Swiss mouse 
model with three dosing regimens. One analogue was effective in the 20 days regimen, reducing 
parasitemia to negligible levels that only reactivated after three cycles of immunosuppression [96]. 
 While remaining controversial as to long term clinical effects, the failure of repurposed 
antifungals in Chagas disease clinical trials has focused attention to drug leads targeting the T. cruzi 
CYP51 (TcCYP51) itself [97, 98]. TcCYP51 is one of the most studied enzymes of T. cruzi as 
represented by crystallographic data for 18 structures of the protein with 16 different ligands in the 
protein databank (ww.rcsb.org). Three structural features make this protein particularly interesting for 
a rational drug design approach: (i) high structure rigidity, particularly in its substrate binding cavity; 
(ii) a substrate access channel in both ligand-free and bound structures that remains open and well 
defined; (iii) a substrate binding cavity that extends deeper inside the molecule than in other CYP 
structures [99]. Figure 3 depicts the key structural regions of TcCYP51: the active site residues within 
the BC-region (residues 100-120, PDB ID: 3KSW sequence numbering) that close the active site and 
isolate the substrate from solvent; the substrate tunnel through which substrate and ligands enter the 
active site; and the deeper substrate regions occupied by smaller ligands such as VNF and LFT (figure 
4A & B) [98, 100, 101]. Some novel compounds designed to target TcCYP51 possess a nitrogen atom 
as a warhead, included in an azole or pyridine heterocycle that are able to form a coordination bond 
with the CYP51 catalytic heme iron and are represented in figure 4A-C. These compounds are simple 
and easy to synthetize and demonstrated strong inhibitory potential of intracellular amastigote growth 
of T. cruzi [98, 102-104]. VNI, in particular, was able to cure infected mice, has oral bioavailability 
and low toxicity, making it an excellent drug candidate [102]. 
 Other enzymes of the ergosterol biosynthesis pathway may be targeted as potential drug targets 
for Chagas disease, including squalene synthase. This enzyme is responsible for the first step of 
ergosterol biosynthesis and was suggested as target in the parasites Leishmania mexicana and T. cruzi 
[105]. The effective and potent squalene synthase inhibitor 4-phenoxyphenoxyethyl thiocyanate 
effective against epimastigote proliferation producing an accumulation of mevalonate pathway 
intermediates is an example of compound targeting this enzyme [106, 107]. E5700, a drug from the 
Eisai Co. which is in development as human cholesterol lowering agent, is efficacious against T. cruzi 
[108]. Amiodarone (figure 2E) also inhibits ergosterol biosynthesis and is currently in clinical trials (as 
well as dronedarone) against the chronic phase of the disease [11]. This antiarrhythmic drug is used in 
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the treatment of cardiac failure in chronic chagasic patients and has been found to act on a synergistic 
manner with azoles in disrupting T. cruzi biology. Amiodarone interferes with the calcium hemostasis 
but also inhibits ergosterol biosynthesis, while posaconazole or itraconazole also affects calcium 
hemostasis, suggesting a viable and advantageous drug combination [109-111]. Allylamine terbinafine, 
a squalene epoxidase inhibitor, and mevinolin inhibit 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase, are antiproliferative against T. cruzi and both have been shown to be synergistic with 
ketoconazole against cultures of the parasite [112], suggesting they could be used in the treatment of 
human Chagas disease [113]. 
 
4.2.CRUZIPAIN INHIBITORS 
 K-777, a vinyl sulfone cysteine protease inhibitor was originally synthesized at Khepri 
Pharmaceuticals as an anti-inflamatory lead (figure 2D). It is an irreversible inhibitor of cruzipain, also 
known as cruzain or gp51/57. Cruzipain is a cathepsin L-like cysteine protease responsible for the 
majority of proteolytic activity in all the stages of T. cruzi. It may be essential for metabolism, 
metacyclogenesis, immune evasion, and invasion of host cells [114-117]. It has been suggested not 
only as a drug target but also as a vaccine target. 
Early experiments with mouse models of Chagas disease showed that cysteine protease inhibitors 
were able to rescue mouse from lethal infection, displaying repetitive negative haemocultures and so 
indicating parasitological cure [118]. K-777 was able to rescue mice from an acute and lethal T. cruzi 
infection even with a non-functional immune system, as seen in immunocompromised patients (e.g. 
HIV/AIDS) or immunosuppressed individuals (e.g. transplantation patients) [119]. K-777 also 
abrogated myocardial damage in beagle dogs treated orally for seven days [120]. 
 Several other classes of inhibitors of cruzipain have been reported as potential drug leads, 
including selenosemicarbazones [121], amidines bearing benzofuroxan or benzimidazole [122], and 
others scaffolds [123, 124]. Effective nitrile inhibitors of cruzipain have also been identified and serve 
to chemically validate this target [125]. 
A variety of approaches has been considered to rationally design inhibitors for cruzipain. Most of 
the compounds synthesized were originally designed to target the catalytic cysteine (Cys) of the 
enzyme in order to obtain irreversible inhibitors. The protein databank reports 24 crystallographic 
structures of cruzipain in complexes with inhibitors. They show that cruzipain is composed of one 
polypeptide chain folded into two domains: one mainly α-helix and the other with an extended 
antiparallel β-sheet. The catalytic triad is composted by Cysteine25, Histidine162 and Asparagine182 
and together with the extended substrate-binding site, they are found in the cleft between the two 
domains [126]. Within the substrate binding site, different regions (S1’, S1, S2 and S3), each devoted 
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to the interaction with and binding of a residues of the peptidic substrate, have been recognized (figure 
5) [127]. Region S2 in particular residue Glutamine208 at its bottom is the key determinant for 
substrate specificity. These residues adopt a substrate-directed conformation in case that the S2 site is 
occupied by a basic or uncharged hydrogen bonding residues (such as Arginine and Tyrosine, 
respectively) whereas it assumes a solvent-directed conformation when an hydrophobic residue (such 
as Phenylalanine) is present [128]. Examples scaffolds designed to inhibit cruzipain are 
acylhydrazones, thiosemicarbazones and methoxyphenyl ketone derivatives. The discovery of 
acylhydrazone compounds as antiparasitic Cys protease inhibitors originated from an high throughput 
screening against brucipain, the major Cys protease of T. brucei [129]. Optimized scaffolds of this 
class of compounds have since been synthesized and also showed to inhibit cruzipain (figure 4D) [130, 
131]. Interestingly, acylhydrazones share some similarity with chalchones, in which the unsaturated 
arylketone subunit can act as a Michael acceptor (figure 6). Chalchones possess anti T. cruzi activity, 
but few studies are associated with cruzipain inhibitory activity [132, 133]. 
After the initial discovery of a peptide vinyl sulfone as an irreversible (Michael acceptor) 
cruzipain inhibitor able to cure parasitic infections in animal models, but with low oral bioavailability 
owing to its peptidic nature, an optimized compound derived from a methoxyphenyl ketone scaffold 
and with desirable physicochemical properties has been reported (figure 4E). Its mechanism of action, 
supported by the crystal structure of the complex, is depicted in figure 7 [134]. 
Thiosemicarbazones are another class of covalent inhibitors originated from a screening of 
compounds able to inhibit cruzipain. Thiosemicarbazones inhibit Cys proteases through the formation 
of a reversible tetrahedral adduct by attack of the Cys thiolate to the carbon of the thiocarbonyl group 
(figure 4F) [135]. However, several members of this class of compounds, inactive on the enzyme, were 
shown to be active on T. cruzi parasites [136-138], suggesting that cruzipain could not be the main 
target for at least some of these compounds. This class of compounds was further modified according 
to the strategy represented in figure 9 [139] and led to compounds that could act in a way that differs 
from a simple cruzipain inhibition. Compound G from figure 4 inhibits cruzipain whereas its 
derivatives, as exemplified by compound in figure 4H, did not, but exhibited strong antiparasitic 
activity. 
 
4.3.PURINE SALVAGE INHIBITORS 
 Allopurinol is an analogue of hypoxanthine that is used to treat gout, a condition characterized by 
deposits of uric acid in bone joints. The mechanism of action for this drug involves the inhibition of 
xanthine oxidase, an enzyme responsible for the consecutive conversion of hypoxanthine to xanthine 
and xanthine to uric acid. T. cruzi is not able to perform de novo synthesis of purines and needs to 
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acquire them from the host. Since the microorganism does not possess xanthine oxidase, allopurinol is 
incorrectly sensed as a purine substrate and is directly incorporated in the parasite DNA by 
hypoxanthine-guanine phosphoribosyltransferase, disrupting DNA-related processes. Previous assays 
showed the potential of the drug in arresting infection in cultured tissues [140], and a later study with 
other purine and pyrimidine analogues confirmed this activity [141]. In an animal model, allopurinol 
was able to reduce parasite blood levels, but with mild cardiac inflammatory infiltrates at the heart. 
Altogether, the results demonstrated the drug modified the evolution of the infection and prevented the 
acute phase from evolving into chronic cardiac disease [142]. A comparative study between 
itraconazole and allopurinol in preventing chronic Chagas disease in Chile showed similar results in 
preventing cardiomyopathy, but itraconazole was preferred due to the fewer adverse effects [143]. A 
combination of allopurinol with clomipramine to treat Chagas disease in an acute mouse model was 
found to be no better than the use of clomipramine alone [144]. Although there has been an interest in 
the label extension of this drug, early clinical evidence have discouraged the development of 
allopurinol as a drug to treat Chagas [145]. There is an interest in exploiting this pathway for Chagas 
chemotherapy, but to our knowledge no other compounds have been recently tested in vivo [146]. 
Several 4'-substituted and 3',4'-disubstituted 5-benzyl-2,4-diaminopyrimidines are selective inhibitors 
of T. cruzi dihydrofolate reductase and showed good in vitro activity against the parasite [147]. 
 
4.4.INHIBITORS OF PYROPHOSPHATE METABOLISM 
 Another pathway that has gained attention is the one responsible for pyrophosphate metabolism. 
This process does not take place in the cytosol but rather at acidocalcisomes, parasite-specific 
organelles that are also involved in calcium hemostasis, response to cell stress, osmoregulation, and 
energy transduction [148]. It has been demonstrated that bisphosphonates, drugs currently used to treat 
osteoporosis, accumulate in the acidocalcisomes and can inhibit a key enzyme of pyrophosphate 
metabolism – farnesyl pyrophosphate synthase [149]. 
 The first report of this activity in animal models demonstrated that risedronate could reduce 
parasitemia with reductions in mortality, but no complete parasitological cures were achieved [150]. In 
another study, a significant reduction in mortality was observed when CD-1 mice were treated with 
risedronate, but myocardial pathology and ventricular dilatation was unchanged in comparison with 
control. On the other hand, Tulahuen strain infected C57BL/6 mice had no improvement in mortality 
[151]. 
 More recently, metal complexes of the bioactive, bisphosphonates alendronate [152] pamidronate 
[152] and risendronate [153] were synthetized and showed activity against amastigotes, with no 
toxicity for the mammalian host cells tested.  These complexes are thought to protect phosphonate 
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groups from ionization at physiological pH, increasing bioavailability to target the parasitic farnesyl 
diphosphate synthase [152]. Newly synthesized bisphosphonates also proved to be potent inhibitors of 
T. cruzi farnesyl diphosphate synthase [154]. 
 
4.5.TRYPANOTHIONE BIOSYNTHESIS INHIBITORS 
 Instead of the glutathione and glutathione reductase, trypanosomatids produce trypanothione and 
trypanothione reductase for thiol-dependent redox metabolism. This is essential in detoxification of 
free radicals and maintenance of the intracellular reducing environment. As this parasite-specific 
system does not exist in the humans, it is considered a potential target [155]. Recently, a study 
validated the trypanothione pathway as drug target with a metabolic modeling approach, suggesting 
that all the constituent enzymes and transporters present are essential for proper pathway function, but 
not all of them have therapeutic potential [156]. Many inhibitors have been found for this enzyme, 
inlcuding polyamine derivatives, crystal violet, acridine-based tricyclics, phenothiazine, benzoazepine, 
isoalloxazine, pyridoquinoline and many more have been synthetized [157-160]. In vivo testing of a 
trypanothione reductase inhibitor, thioridazina, promoted heart protection but failed to completely 
eradicate the parasite [161]. 
 
4.6.LIPID BIOSYNTHESIS INHIBITORS 
Alkyllysophospholipids and lysophospholipid analogues, such as miltefosine and edelfosine have 
been shown to be active against proliferation and differentiation of T. cruzi, in vitro and in vivo with 
good oral activity and low toxicity [162-167]. 
Surprisingly little is known about the role of glycosphingolipids in trypanosomatids, however, 
various glycosphingolipids inhibitors have shown antiproliferative activity lysing 79 to 95.5% of 
parasite in an in vitro assay and showed cytostatic activity in mouse model [168]. 
Although T. cruzi glycophosphatidylinositol GPI anchors share the same conserved core as other 
eukaryotes, many often contain a fourth mannose on which resides a galactofuranosyl (Galf) linked to 
the O-3 and an obligatory 2-aminoethylphosphonate (2AEP), also known as ciliatine, linked to O-6 of 
the glucosamine of all T. cruzi GIPLs and GPI-anchored mucins [169-171]. 
Enzymes common to the biosynthesis of the T. cruzi GPI have been shown to have sensitivities to 
various inhibitors in different organisms [172, 173]. A recent work identified the orthologous 
sequences of all genes involved in the biosynthesis of the T. cruzi GPI and three sequences showed 
they acted to complement yeast conditional mutants of genes of this pathway. Unsuccessful attempts to 
generate T. cruzi knockouts for three of these genes further suggested that the GPI is an essential 
component of the organism [174]. 
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Although the role of 2AEP in T. cruzi has not yet been identified, it has been shown to be a 
virulence factor in human pathogenic organisms such as Bacteroides fragilis [175]. The absence of the 
2AEP biosynthetic enzymes (phosphoenolpyruvate mutase, phosphoenolpyruvate decarboxylase & 2- 
aminoethylphosphonate transaminase) in humans, make the pathway an excellent candidate for drug 
targeting. Recent investigations by Coron and Smith (unpublished) have genetically validated the AEP 
biosynthetic pathway and identified compounds with potent in vitro activity against the recombinant 
enzymes of the 2AEP pathway as well as epimastigotes. 
 
CONCLUSION 
 
 Since the discovery of the etiological agent of Chagas disease more than 100 years ago, a cure 
has been pursued. It took 50 years to discover a specific drug to treat this neglected disease. However, 
apart from the discovery and development of benznidazole some years later, no improvements in 
chemotherapy have been made compared to these highly toxic compounds despite a half century of 
intense research.  Nevertheless, there are reasons to be optimistic. The global nature of the disease and 
the information about its pathology, has brought new researchers to the field. Novel basic and applied 
research is constantly feeding our knowledge of the disease. New partnerships, including with 
pharmaceutical companies, are accelerating efforts traditionally made solely by academia. Clinical 
trials for some candidates have been recently completed, some are under way and a few more are 
planned to begin shortly. But we should not ignore the still long way and challenges to find a better 
treatment for Chagas: resources and funding are scarce, and there is a critical need to define beneficial 
intellectual property agreements and improve data sharing. 
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Figures 
 
Figure 1. Current drugs for Chagas disease: (A) benznidazole and (B) nifurtimox.  
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Figure 2. Drugs on the pipeline for Chagas disease: (A) posaconazole, (B) E1224, (C) Tak187, (D) K-
777, (E) amiodarone. 
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Figure 3: TcCYP51 crystallographic structure (PDB ID: 3KSW). The protein is represented as a gray 
ribbon, the BC-region that close the active site and includes residues important of the catalytic activity 
is colored in red, residues surrounding the entrance of the substrate channel are colored in blue. Inside 
the enzyme, the heme group is colored in green with atoms represented as sphere; the binding cavity is 
occupied by ligands (POZ (PDB ID: 3K1O) and VNF (PDB ID: 3KSW)), whose atoms are represented 
by sphere and colored as follow: purples the moieties that occupy the substrate channel; orange the 
moieties that occupy the deeper binding region; cyan the moieties involved in the interaction with the 
heme group. 
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Figure 4 – Molecular structure of scaffolds currently being in study for Chagas Disease. 
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Figure 5. Crystallographic structure of cruzipain in complex with a non-peptidic vinylsulfone 
derivative (PDB-ID: 3HD3). The protein is represented as a surface colored in gray, specific sites are 
colored as follow: S1’ in cyan, S1 in purple, S2 in yellow, S3 in green. The ligand in represented in 
stick, colored by-atom as follow: C in black, O in red, N in blue, S in yellow. 
 
Figure 6: Similarity between chalchones and N-acylhydrazones. 
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Figure 7: Mechanism of inactivation of cruzipain by a tetrafluorophenoxymethyl ketone derivative. 
 
Figure 8: Mechanism of inactivation of Cys proteases by thiosemicarbazones. 
 
Figure 9: Design of hydrazones as anti T. cruzi parasites. 
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Figure 3: TcCYP51 crystallographic structure (PDB ID: 3KSW). The protein is represented as a gray ribbon, 
the BC-region that close the active site and includes residues important of the catalytic activity is colored in 
red, residues surrounding the entrance of the substrate channel are colored in blue. Inside the enzyme, the 
heme group is colored in green with atoms represented as sphere; the binding cavity is occupied by ligands 
(POZ (PDB ID: 3K1O) and VNF (PDB ID: 3KSW)), whose atoms are represented by sphere and colored as 
follow: purples the moieties that occupy the substrate channel; orange the moieties that occupy the deeper 
binding region; cyan the moieties involved in the interaction with the heme group.  
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Figure 5. Crystallographic structure of cruzipain in complex with a non-peptidic vinylsulfone derivative (PDB-
ID: 3HD3). The protein is represented as a surface colored in gray, specific sites are colored as follow: S1’ in 
cyan, S1 in purple, S2 in yellow, S3 in green. The ligand in represented in stick, colored by-atom as follow: 
C in black, O in red, N in blue, S in yellow.  
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